该公司还维持了今年利润增长7%至9%的指引。部分分析师此前预计的指引约为每股收益增长 6%至8%，新任首席执行官卢克·米尔斯为这一年设定了一个可能被超越的目标，其中抗癌药物 Blenrep有望提振收入。 葛兰素史克预计 2026 年营业额增长 3% 至 5%；核心营业利润增长 7% 至 9%；核心每股收 益增长 7% 至 9%。该公司预计到 2031 年销售额将超过 400 亿英镑。 葛兰素史克(GSK.US) 第四季度利润高于预期，这主要得益于其艾滋病(HIV)药物以及一款现已获批用 于治疗肺部疾病的哮喘药物。财报显示，葛兰素史克四季度营收达 86.2 亿英镑，同比增长 6.3%，超 出预期 1.7 亿英镑；调整后每股收益为 25.5 便士(约合 35 美分)，高于分析师的预期。 该公司经营活动产生的现金流为 89 亿英镑，自由现金流为 40 亿英镑。 在前CEO沃尔姆斯利执掌期间，葛兰素史克拆分了其消费者健康部门 Haleon，并进行了关键收 购以尝试增强其药物研发管线。尽管如此，米尔斯仍需向投资者证明，公司能够实现本十年末及 更长远时期的营收抱负。上个月，葛兰素史克同意以 22 亿美元的交易价格收购总部 ...

Core Viewpoint - GlaxoSmithKline (GSK) reported better-than-expected fourth-quarter profits, driven by its HIV drug and an asthma medication approved for lung disease treatment [1] Financial Performance - GSK's fourth-quarter revenue reached £8.62 billion, a year-on-year increase of 6.3%, exceeding expectations by £170 million [1] - Adjusted earnings per share were 25.5 pence (approximately 35 cents), surpassing analyst forecasts [1] - The company maintained its profit growth guidance for the year at 7% to 9%, with previous analyst expectations at 6% to 8% [1] - GSK expects revenue growth of 3% to 5% by 2026, with core operating profit and core earnings per share also projected to grow by 7% to 9% [1] - The company anticipates sales will exceed £40 billion by 2031 [1] - Cash flow from operations was £8.9 billion, with free cash flow at £4 billion [1] Product Portfolio and Market Challenges - GSK faces a significant "patent cliff" for its best-selling HIV drug, with expectations of low double-digit growth for its specialty drug portfolio, which includes HIV and cancer medications [2] - The vaccine and generic drug segments may experience revenue declines, influenced by changing sentiments in the U.S. under Health Secretary Robert F. Kennedy [2] - Despite challenges, the vaccine business performed better than expected last quarter, driven by increased demand outside the U.S., particularly for GSK's shingles vaccine in China [2] Strategic Moves - Under former CEO Emma Walmsley, GSK spun off its consumer health division Haleon and made key acquisitions to enhance its drug development pipeline [2] - New CEO Luke Mills must demonstrate to investors that the company can achieve its revenue ambitions for the end of this decade and beyond [2] - Recently, GSK agreed to acquire U.S.-based biotechnology company Rapt Therapeutics for $2.2 billion, focusing on therapies for inflammation and immune system diseases [2]

Group 1: Company Performance - Pfizer's stock is down by 5%, while Merck is holding up better [1] - Merck's guidance raised concerns due to loss of exclusivity (LOE) issues, but investors are more optimistic about its pipeline following numerous business development (BD) deals [2][3] - Pfizer's fourth quarter performance was solid with no change to guidance, but competitive metadata in phase two development of their GLP-1 drug indicates potential [3] Group 2: Investment Outlook - A neutral rating is given for both Pfizer and Merck, with a preference for Merck due to its aggressive business development efforts, despite ongoing patent cliff concerns [3][4] - The focus is on growth-oriented stocks in the sector, with Eli Lilly, Gilead, and Vertex being favored for their clean growth stories [5][6] - Future stock performance will depend on capital deployment strategies such as business development, dividend hikes, and buybacks [7]

好的，各位投资人，晚上好，然后欢迎参加我们的医药每周谈第 236 期，关于 GP MOOC 2026 的海外公司的一个进展。然后我是中银建投医药分析师徐颖翔。然后就是关于整个 Gilead 海外公司的一个情况吧。我们可以看得出来，在整个基于摩根这个期间的话，海外 的药企主要就是在一个专利悬崖的一个压力下面，是加速转型与和与技术兑现。大部分跨 国药企的话，是通过一个大规模的 BD 和并购来平滑自己重磅产品专利的到期的一个销售 冲击。包括默沙东规划 700 亿美元的一个新的产品组合，BMS 的话这几年也完成了 300 亿美元的一个并购交易，阿斯利康的话也是目标在 2030 年能够实现一个 800 亿美元的一 个营收。 因此这几年的话，整个受并购与 BD 还是各家跨国药企最重要的一个战略布局的一个方向， 主要也就是为了应对专利悬崖，同时聚焦高确定性的资产，以及技术平台的一个补强。另 一方面的话，也是整个 AI，从工具也上升到了一个制药的一个核心生产力。成为整个制药 行业的一个核心的驱动，驱动力之一。多家跨国药企，包括礼来、阿斯利康、赛诺菲，都 在 GD Morgan 期间。通过与英伟达以及各种其他的 AI 公司达成 ...

Core Insights - Roche, once a dominant player in oncology, has shown a revenue growth of 7% and a 9% increase in its pharmaceutical business, indicating a strategic recovery and diversification in its product portfolio [1][3] - The company is focusing on six key products, including Phesgo and Polivy, which are driving growth and compensating for declines in older drugs due to patent expirations [1][5] - Roche plans to launch 19 new drugs by 2030, with 16 having blockbuster potential, aiming to avoid the so-called "patent cliff" [1][3] Oncology Business - Roche's oncology segment has seen continuous growth for eight consecutive quarters, contributing 239.38 billion Swiss Francs (approximately 289.5 billion USD) in 2025, a 6% year-over-year increase [3] - Phesgo has emerged as a standout product with a 48% sales increase, leveraging its innovative dual-target subcutaneous formulation [5][6] - The HER2-targeted therapies are expected to peak at around 9 billion Swiss Francs by 2026, with a stable revenue stream projected thereafter [6] New Drug Developments - Roche is optimistic about Giredestrant, a new oral SERD for ER-positive breast cancer, which is anticipated to become a first-line treatment option, with peak sales expectations exceeding 3 billion USD [7][8] - The company has achieved significant milestones in clinical trials, particularly with the lidERA study, which shows promise in reducing recurrence risk in early-stage breast cancer patients [7] Hematology Sector - Roche's hematology products generated 86 billion Swiss Francs in 2025, marking a 15% increase, with Polivy being a key driver of this growth [9][10] - Polivy has become a leading first-line treatment for diffuse large B-cell lymphoma (DLBCL), achieving sales of 14.7 billion Swiss Francs in 2025, a 38% increase [10] Strategic Expansion into Chronic Diseases - Roche is diversifying its portfolio by investing over 20 billion USD in chronic disease areas such as obesity and Alzheimer's, aiming to become a top player in the obesity market [11][12] - The company has made significant acquisitions and partnerships to build a robust pipeline in obesity treatments, including GLP-1 receptor agonists and long-acting insulin analogs [11][15] Future Outlook - Roche's strategy emphasizes maintaining a diverse product portfolio to mitigate risks associated with patent expirations, with a focus on innovative therapies in various therapeutic areas [12][16] - The next few years will be critical for validating Roche's ambitious plans and determining the sustainability of its new growth trajectory [18]

Summary of Conference Call Notes Industry: Storage Chips - HBF is expected to partially replace HBM in AI servers, balancing performance and cost, with mass production anticipated in Q4 2026 to Q1 2027 at a price of approximately $10–11 per GB [1][2] - HBF is beneficial for SanDisk and Kioxia as they do not engage in HBM business, allowing them to expand their market through HBF [1][2] - Current supply and demand for HBM are generally balanced [1][2] - Production capacity is planned to expand to 476,000 wafers per month by 2026, suggesting a stable to declining price for HBM in 2026 [2] Industry: RF Chips - The RF chip industry is expected to see moderate recovery in 2026, with intense price competition in the 4G sector, while the 5G sector's L-PAMiD modules maintain a profit margin exceeding 20% with relatively eased competition [2] - Satellite direct connection in mobile phones is emerging as a new growth area, with the Mate80 series supporting low-altitude direct connection, primarily in collaboration with Zhaoshengwei; Xiaomi, Vivo, OPPO, and Samsung are following suit [2] Industry: AI Programming - Current AI programming tools are categorized into three main types: plugin-based, AI-native IDEs, and Agent types, represented by GitHub Copilot, Cursor, and Claude Code respectively [2] - GitHub Copilot shows the fastest commercialization progress with a monthly active user payment rate exceeding 20%; Cursor's latest ARR has reached $1 billion; Claude Code's API call volume is approximately 60% of Anthropic's, indicating significant revenue potential [3] - Leading domestic programming models include DeepSeek, Zhipu, Alibaba Qianwen, and Kimi, with a focus on the B-end market, while C-end free IDE products are currently underperforming [3] Industry: Tires - The global demand for giant tires is expected to grow by 35% from 2025 to 2029, driven primarily by increased demand from overseas mining projects [3] - Foreign brands like Michelin, Bridgestone, and Goodyear plan to raise giant tire prices by over 10% in 2026, while domestic brands like Hai'an will not increase prices to capture market share [3] - Hai'an's overseas growth this year is primarily focused on markets in Russia, Northwest Africa, and South Africa, with other domestic brands like Sailun and Zhongce also accelerating their international expansion [3] Industry: Pharmacies - Recent policy documents appear macro in nature and lack specific measures, but they provide a framework and space for subsequent detailed regulations from various ministries [3] - The industry is still undergoing a natural clearance process, with an expected annual exit of 10,000 to 20,000 stores, predicting a dynamic balance when the total number of stores stabilizes around 600,000 [3] - The O2O average transaction value has increased from below 50 yuan to approximately 55 yuan, with future O2O growth expected to maintain over 20% [3] Industry: Innovative Drugs - Competition in the CXO sector from South Korea is intensifying, with Samsung entering the ADC and cell therapy production markets [4] - To address patent cliff issues, BMS has launched seven new core products, while Merck has engaged in extensive mergers and acquisitions to enter new disease areas [4] - Major pharmaceutical companies are actively investing in AI, but few have the capability for significant computational investment like Eli Lilly [4]

Core Insights - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) for a licensing agreement valued at up to $18.5 billion, focusing on the development of obesity and diabetes medications [1][2] - The partnership will leverage CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform to jointly develop innovative long-acting peptide drugs [1] - This agreement marks CSPC's largest business development deal to date, with potential total payments reaching $18.5 billion if all milestones are achieved [2] Financial Aspects - CSPC will receive an upfront payment of $1.2 billion, with the potential for up to $3.5 billion in research milestone payments and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [1][2] - The deal is expected to significantly support AstraZeneca's pipeline for obesity drugs, which currently includes three candidates at various stages of development [5] Market Context - The global obesity drug market is projected to reach $100 billion by 2030, indicating a rapidly growing sector where AstraZeneca aims to compete against established players like Novo Nordisk and Eli Lilly [5] - The collaboration is part of a broader trend where multinational pharmaceutical companies are increasingly investing in the Chinese market, driven by the need for high-quality drug pipelines amid patent expirations and declining R&D efficiency [6][7] Strategic Importance - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and R&D, which is crucial for achieving its goal of launching 20 innovative drugs by that year [6] - The partnership with CSPC is seen as a complement to AstraZeneca's investment strategy in China, reinforcing its commitment to local innovation and development [6] Industry Trends - By 2025, China's innovative drug licensing transactions are expected to exceed $130 billion, reflecting a significant increase in the number of deals and the value of Chinese biotech assets [7] - The shift from simple licensing to more complex collaborations indicates that Chinese pharmaceutical companies are poised to capture a larger share of the global pharmaceutical value chain [7][8]

Core Viewpoint - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) to develop obesity and diabetes drugs, with a maximum value of $18.5 billion, aiming to strengthen its position in a rapidly growing market [1][2]. Group 1: Collaboration Details - The agreement allows AstraZeneca exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, produce, and commercialize a weight management product portfolio, including one project entering clinical trials and three preclinical projects [1]. - CSPC will receive a $1.2 billion upfront payment, with potential milestone payments of up to $3.5 billion for development and $13.8 billion for sales, plus a double-digit percentage royalty based on annual net sales of the licensed products [1][2]. Group 2: Market Context - If all milestones are achieved, CSPC could receive a total of $18.5 billion, making it the largest business development deal for the company to date [2]. - The deal is expected to surpass recent significant transactions in the obesity drug market, including Pfizer's acquisition of a weight loss drug startup for over $10 billion [5]. Group 3: Strategic Importance - This collaboration supports AstraZeneca's pipeline for obesity drugs, with three treatments currently in various stages of development, and positions the company to compete in a market dominated by Novo Nordisk and Eli Lilly [5]. - Analysts predict that the global obesity drug market could reach $100 billion by 2030, highlighting the strategic importance of this collaboration for AstraZeneca [5]. Group 4: Investment in China - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and research, which is crucial for achieving its goal of launching 20 innovative drugs by 2030 [6]. - The partnership with CSPC is seen as a complement to this investment strategy, reflecting the increasing focus of multinational pharmaceutical companies on the Chinese market [6]. Group 5: Industry Trends - The Chinese pharmaceutical market is experiencing a surge in innovation, with projections indicating that by 2025, the total value of innovative drug licensing transactions will exceed $130 billion [7]. - The industry is evolving from simple licensing agreements to more complex collaborations, allowing Chinese pharmaceutical companies to capture a larger share of the global pharmaceutical value chain [7][8].

Core Viewpoint - Sanofi's strong sales performance of Dupixent has driven better-than-expected earnings for Q4 2025, with continued revenue and profit growth anticipated in 2026 [1] Financial Performance - Q4 2025 net sales reached €11.303 billion, a year-on-year increase of 7.0% (13.3% at constant exchange rates) [2] - Business operating income for Q4 was €2.341 billion, up 12.7% year-on-year [2] - Business net income for Q4 was €1.856 billion, reflecting a 13.0% increase year-on-year [2] - Business earnings per share (EPS) for Q4 was €1.53, a 16.8% increase compared to the previous year [2] - Free cash flow for Q4 was €2.637 billion, up 12.7% year-on-year [2] Product Performance - Dupixent sales grew by 32.2% year-on-year to a record €4.246 billion in Q4, solidifying its position as a key growth driver for Sanofi [2] - The pharmaceutical segment's sales increased by 49.4% to €1.121 billion, primarily driven by Ayvakit and ALTUVIIIO [2] Future Outlook - Sanofi expects sales growth in 2026 to be in the high single-digit percentage range (at constant exchange rates), with business EPS growth slightly exceeding sales growth [3] - The company plans to execute a €1 billion share buyback program in 2026 [3] Challenges and Strategic Focus - Sanofi's vaccine business faced a 2.5% decline in Q4 sales to €2.039 billion, with expectations of a slight decrease in vaccine sales for 2026 [3] - CEO Paul Hudson expressed optimism about sustained profit growth for at least five years, but emphasized the need for a robust pipeline to reduce reliance on Dupixent [4] - Recent disappointing trial results for new drugs have raised concerns about Sanofi's ability to generate sufficient revenue from upcoming products [4] - The company has written down €2.24 billion, primarily related to the failed multiple sclerosis drug tolebrutinib [4] Strategic Initiatives - Following the divestiture of its consumer health business, Sanofi is focused on demonstrating the success of its "pure innovation" strategy [5] - The company has engaged in significant partnerships, including a $1.04 billion collaboration with ADEL for an early-stage Alzheimer's antibody and a potential $1.7 billion deal with Dren Bio to enhance its autoimmune platform [5]

Core Insights - Sales of Bristol Myers Squibb's (BMS) and Pfizer's drug Eliquis (apixaban) are projected to decline by 15.2% due to the loss of European market exclusivity on May 19, 2026, marking the beginning of a significant patent cliff [1] - Eliquis has generated approximately $82.6 billion in revenue since its launch in 2011, dominating the anticoagulant market [1] - The compound annual growth rate of Eliquis' global sales has been 108.3% since its introduction, with a peak forecasted at just under $14.2 billion in 2025, followed by a predicted 92.3% decline by 2030 compared to 2025 [3] Market Dynamics - Eliquis entered the European market in May 2011 and has revolutionized thromboprophylaxis by preventing clot formation through direct and reversible inhibition of factor Xa, distinguishing it from traditional anticoagulants [2] - The drug's higher safety profile and reduced monitoring needs have led to its adoption as a first-line treatment for various cardiovascular diseases [2] Revenue and Patent Strategy - BMS and Pfizer have attempted to extend Eliquis' market exclusivity through a supplementary protection certificate (SPC) filing, generating approximately $29.5 billion in additional revenue and delaying the patent cliff [3] - With US patent expiry expected in 2028, BMS and Pfizer are launching a direct-to-patient Eliquis option in July 2025, offering over 40% reduction for prescriptions to underinsured, uninsured, or self-pay patients [5] - This program aims to mitigate competition and expand market access, targeting cash-paying patients who make up to 10% of the patient population [5]